-
If you purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
October 21, 2016 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) was announced over potential breaches of fiduciary duties by certain officers and directors at Rigel Pharmaceuticals.
The investigation by a law firm concerns whether certain Rigel Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Rigel Pharmaceuticals, Inc. reported that its annual Total Revenue increased from $8.25 million in 2014 to $28.89 million in 2015 and that its Net Loss declined from $90.91 million in 2014 to $51.46 million in 2015. Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) grew from $2.13 per share in July 2016 to as high as $4.11 per share on October 5, 2016.
On October 20, 2016, Rigel Pharmaceuticals, Inc. reported results from the second FIT phase 3 study and the long-term open-label extension study for Fostamatinib in adult chronic/persistent immune thrombocytopenia (ITP).
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) declined to as low as $1.95 per share on October 20, 2016.
On October 21, 2016, NASDAQ:RIGL shares closed at $2.59 per share.
